Cellular Carbon-Film-Based Flexible Sensor and Waterproof Supercapacitors.

ACS Appl Mater Interfaces

CityU-Xidian Joint Laboratory of Micro/Nano-Manufacturing , Shenzhen 518057 , China.

Published: July 2019

A highly sensitive portable piezoresistive sensor with a fast response time in an extended linear working range is urgently needed to meet the rapid development of artificial intelligence, interactive human-machine interfaces, and ubiquitous flexible electronics. However, it is a challenge to rationally couple these figures of merit (sensitivity, response time, and working range) together as they typically show functionally correlative behavior in the sensor. Here, we aim at introducing the hierarchical pores across several size orders from micro- to larger scale into the intrinsically flexible graphene-based electrode materials that overcome this limitation of the sensor. We achieved a flexible sensor with a prominent sensitivity of 11.9 kPa in the linear range of 3 Pa to ∼21 kPa and a rapid response time of 20 ms to positively monitor the pulse rate, voice recognition, and true force value for biomedical and interactive human-machine interface application assisted by an analog-digital converter. More interesting is the carbon-nanotube-doped graphene that also served as the electrode in the waterproof supercapacitor to actively drive the sensor as a whole flexible system. We believe our findings not only offer a general strategy for the graphene-based platform in flexible electronics but also possess other intriguing potential in functional application such as the heat dissipation component in electron devices or seawater filtration in environment application.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsami.9b09438DOI Listing

Publication Analysis

Top Keywords

response time
12
flexible sensor
8
working range
8
interactive human-machine
8
flexible electronics
8
flexible
6
sensor
6
cellular carbon-film-based
4
carbon-film-based flexible
4
sensor waterproof
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Center for Health + Technology, University of Rochester Medical Center, Rochester, NY, USA.

Background: In preparation for therapeutic trails involving patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI), there is a need for valid, disease-specific caregiver-reported outcome (CRO) measures capable of tracking symptomatic burden in response to therapy over time. CROs are useful tools in clinical trials for individuals with AD, MCI, and dementia who are unable to self-report. In addition, CROs are accepted by the United States Food and Drug Administration to support regulatory claims.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Background: Clinical trials should strive to yield results that are clinically meaningful rather than solely relying on statistical significance. However, the determination of clinical meaningfulness of dementia clinical trials lacks standardization and varies based on the trial's nature. To tackle this issue, a proposed approach involves assessing the time saved before reaching a specific threshold in cognitive status.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Axsome Therapeutics, New York, NY, USA.

Background: Patients with Alzheimer's disease (AD) often experience burdensome neuropsychiatric symptoms, including agitation which occurs in both home and long-term care (LTC) facilities, and is associated with substantial increases in caregiver burden and LTC placements. AXS-05 (45-mg dextromethorphan/105-mg bupropion), a novel, oral NMDA receptor antagonist and sigma-1 receptor agonist, approved by the FDA for major depressive disorder, is being investigated for treatment of AD agitation (ADA). AXS-05 has been evaluated in 2 randomized, double-blind studies: Phase 2 ADVANCE-1 (NCT03226522); Phase 3 ACCORD (NCT04797715).

View Article and Find Full Text PDF

Background: Understanding the fundamental differences between the human and pre-human brain is a prerequisite for designing meaningful models and therapies for AD. Expressed CHRFAM7A, a human restricted gene with carrier frequency of 75% in the human population predicts profound translational significance.

Method: The physiological role of CHRFAM7A in human brain is explored using multiomics approach on 600 post mortem human brain tissue samples (ROSMAP).

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Center for Health + Technology, University of Rochester Medical Center, Rochester, NY, USA.

Background: To bolster clinical trial infrastructure, there is a need to develop novel, valid, and reliable patient-reported outcome (PRO) measures capable of tracking clinically-relevant changes in Alzheimer's disease (AD), Mild Cognitive Impairment (MCI) and dementia over time. This research describes the development and validation of the Alzheimer's Disease-Health Index (AD-HI) as a tool to measure how patients feel and function in response to therapeutic intervention.

Method: We previously conducted semi-structured qualitative interviews and a national cross-sectional study with individuals with AD, MCI and dementia to ascertain the most prevalent and impactful symptoms identified by the participants.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!